Distribuzione geografica
Continente #
NA - Nord America 8.216
EU - Europa 2.566
AS - Asia 651
Continente sconosciuto - Info sul continente non disponibili 11
SA - Sud America 5
AF - Africa 4
OC - Oceania 1
Totale 11.454
Nazione #
US - Stati Uniti d'America 8.053
CN - Cina 496
SE - Svezia 483
UA - Ucraina 478
IT - Italia 443
DE - Germania 437
CA - Canada 163
GB - Regno Unito 152
FI - Finlandia 118
IE - Irlanda 115
AT - Austria 108
VN - Vietnam 75
FR - Francia 62
DK - Danimarca 43
RU - Federazione Russa 38
BE - Belgio 34
NL - Olanda 27
TR - Turchia 22
IN - India 19
JP - Giappone 11
EU - Europa 9
HK - Hong Kong 8
IR - Iran 8
PL - Polonia 7
ES - Italia 6
KR - Corea 6
RO - Romania 5
BR - Brasile 4
CH - Svizzera 3
RS - Serbia 3
TW - Taiwan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BG - Bulgaria 2
SC - Seychelles 2
ZA - Sudafrica 2
AU - Australia 1
CZ - Repubblica Ceca 1
EC - Ecuador 1
IL - Israele 1
MK - Macedonia 1
PK - Pakistan 1
SG - Singapore 1
Totale 11.454
Città #
Ann Arbor 1.842
Woodbridge 1.187
Fairfield 673
Houston 663
Jacksonville 519
Chandler 414
Wilmington 398
Frankfurt am Main 343
Dearborn 335
Ashburn 306
Seattle 286
Cambridge 254
Princeton 214
Dublin 110
Vienna 108
Altamura 104
Nanjing 104
Lawrence 102
Milan 93
Lachine 91
Beijing 67
Fremont 49
Andover 45
San Diego 42
Nanchang 37
Hebei 34
Ottawa 34
Brussels 33
Jiaxing 28
Toronto 28
Guangzhou 27
Shenyang 27
Boardman 26
Helsinki 25
Changsha 23
Huizen 22
Philadelphia 21
Tianjin 21
Falls Church 19
Norwalk 18
Kunming 17
Lissone 16
London 16
Detroit 15
Hangzhou 14
Mountain View 13
Shanghai 11
Dong Ket 10
Los Angeles 10
Jinan 9
University Park 9
Auburn Hills 8
Redmond 8
Chicago 7
Edmonton 7
Lanzhou 7
Leawood 7
Kiev 6
Sacramento 6
San Mateo 6
Chiswick 5
Florence 5
Fuzhou 5
Hefei 5
Kraków 5
Rome 5
Taizhou 5
Tappahannock 5
Torre Del Greco 5
Brescia 4
Changchun 4
Dallas 4
Moscow 4
Ningbo 4
Palermo 4
Zanjan 4
Zhengzhou 4
Castelleone 3
Central 3
Cormano 3
Grottaglie 3
Henderson 3
Istanbul 3
Kocaeli 3
Loreto 3
Miami 3
Padova 3
Perugia 3
Taipei 3
Turin 3
Wuhan 3
Aci Catena 2
Ardea 2
Bangalore 2
Belgrade 2
Carate Brianza 2
Carugate 2
Castelnuovo Rangone 2
Cermenate 2
Chengdu 2
Totale 9.111
Nome #
High-dose epirubicin in patients with advanced or recurrent uterine sarcoma 484
Oncologic and fertility impact of surgical approach for borderline ovarian tumours treated with fertility sparing surgery 320
Ovarian function, fertility, and menopause occurrence after fertility-sparing surgery and chemotherapy for ovarian neoplasms 259
Genomic and epigenomic profile of uterine smooth muscle tumors of uncertain malignant potential (Stumps) revealed similarities and differences with leiomyomas and leiomyosarcomas 227
Potential role of BCL2 in the recurrence of uterine smooth muscle tumors of uncertain malignant potential 225
Clinical outcome of patients with malignant tumors associated with mature cystic teratomas of the ovary: A retrospective multicenter Italian study 209
Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer 178
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial 178
From Conventional Radiotracer Tc-99m with Blue Dye to Indocyanine Green Fluorescence: A Comparison of Methods Towards Optimization of Sentinel Lymph Node Mapping in Early Stage Cervical Cancer for a Laparoscopic Approach 173
Early-stage clear cell ovarian cancer compared to high-grade histological subtypes: An outcome exploratory analysis in two oncology centers 166
Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production 163
Adjuvant sequential chemo and radiotherapy improves the oncological outcome in high risk endometrial cancer 161
Imact of bevacizumab-containing primary treatment on outcome of recurrent ovarian cancer: An Italian study 161
Early and short-term complications after US-guided puncture of gynecologic lesions: evaluation after 1,000 consecutive cases 150
OC13. 02: Reproducibility of IETA terms in describing endometrial pathology 147
Pre-operative morphological and colour Doppler features of borderline ovarian tumours 147
Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group 146
Ultrasound, physical examination, and CA 125 measurement for the detection of recurrence after conservative surgery for early borderline ovarian tumors 145
Randomized phase III clinical trial evaluating weekly cisplatin for advanced epithelial ovarian cancer 145
The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale 141
Sentinel lymph node detection in endometrial cancer: hysteroscopic peritumoral versus cervical injection 140
Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study 139
Uterine leiomyosarcoma: analysis of treatment failures and survival 139
External validation of diagnostic models to estimate the risk of malignancy in adnexal masses 138
Prospective multicenter study on the clinical utility of CA 72.4 in post-menopausal patients with pelvic mass 133
Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale 130
Prospective multicenter study on CA 125 in postmenopausal pelvic masses 130
Role of puncture and aspiration in expectant management of simple ovarian cysts: a randomised study 126
Brachytherapy for isolated vaginal recurrences from endometrial carcinoma 125
Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy 122
Proliferative response of lymphocytes from ovarian cancer patients to autologous tumor cells 121
Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies 120
Endometrial stromal sarcoma: analysis of treatment failures and survival 120
Long-term toxicity and health-related quality of life after adjuvant chemoradiotherapy or radiotherapy alone for high-risk endometrial cancer in the randomised PORTEC-3 trial 120
Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas 119
Adnexal masses difficult to classify as benign or malignant using subjective assessment of gray-scale and Doppler ultrasound findings: logistic regression models do not help 119
Clinical behavior of 203 stage II endometrial cancer cases: the impact of primary surgical approach and of adjuvant radiation therapy 119
Synchronous early-stage endometrial and ovarian cancer 118
Cisplatin-, epirubicin- and paclitaxel-containing chemotherapy in uterine adenocarcinoma 117
Long-term clinical benefits of neoadjuvant chemotherapy in women with locally advanced cervical cancer: Validity of pathological response as surrogate endpoint of survival 116
Antiemetic efficacy of granisetron in patients with gynecological malignancies 115
Intense neoadjuvant chemotherapy with cisplatin and epirubicin for advanced or bulky cervical and vaginal adenocarcinoma 114
Safety of transvaginal fine needle puncture of gynecologic masses: a report after 500 consecutive procedures 114
Ovarian cancer prediction in adnexal masses using ultrasound based logistic regression models: a temporal and external validation study by the IOTA group 113
Optimal treatment of early-stage ovarian cancer 113
Ultrasound in the follow-up of young patients with malignant ovarian tumors after conservative surgery 110
Carcinosarcoma of the uterus: a clinicopathological multicenter CTF study 110
Dose-dense neoadjuvant chemotherapy with paclitaxel and carboplatin in cervical cancer: Efficacy on pathological response 108
Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis 107
Lesion size affects diagnostic performance of IOTA logistic regression models, IOTA simple rules and risk of malignancy index in discriminating between benign and malignant adnexal masses 107
Color Doppler ultrasound in the preoperative assessment of adnexal masses 106
Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients 105
Changes in the management and outcome of central nervous system involvement from ovarian cancer since 1994 100
Endometriomas: Their ultrasound characteristics 99
A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis 98
A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collaborative Study 97
Effectiveness of autologous blood transfusion in patients undergoing radical hysterectomy 96
Imaging in gynecological disease (7): clinical and ultrasound features of Brenner tumors of the ovary 96
Primary carcinoma of the fallopian tube. A retrospective analysis of 47 patients 96
International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer 95
Ultrasound characteristics of endometrial hyperplasia described using IETA terms 94
A phase II clinical trial of topotecan and carboplatin in patients with newly diagnosed advanced epithelial ovarian cancer 93
Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes 93
Transvaginal ultrasonographic characterization of ovarian masses: comparison of five scoring systems in a multicenter study 92
Primary malignant vaginal melanoma treated with adriamycin and ifosfamide: a case report and literature review 91
Second-look laparotomy in the management of fallopian tube carcinoma 91
Clinically oriented three-step strategy to the assessment of adnexal pathology 91
Clindamycin-paclitaxel pharmacokinetic interaction in ovarian cancer patients 89
Secondary analyses from a randomized clinical trial: age as the key prognostic factor in endometrial carcinoma 88
Intraperitoneal recombinant gamma-interferon in patients with recurrent ascitic ovarian carcinoma: modulation of cytotoxicity and cytokine production in tumor-associated effectors and of major histocompatibility antigen expression on tumor cells 87
Modified radical hysterectomy versus extrafascial hysterectomy in the treatment of stage I endometrial cancer: results from the ILIADE randomized study 86
A novel approach to predict the likelihood of specific ovarian tumor pathology based on serum CA-125: a multicenter observational study 86
Cell cycle-related phosphatases CDC25A and B expression correlates with survival in ovarian cancer patients 86
The prognostic relevance of histological type in uterine sarcomas: A cooperation task force (CTF) multivariate analysis of 249 cases 82
Alpha-fetoprotein in the management of germ cell tumors of the ovary 80
Ifosfamide in the treatment of malignant epithelial ovarian tumors 79
Metabolism of tumour-derived urokinase receptor and receptor fragments in cancer patients and xenografted mice 79
Detection of abnormal intrauterine vascularization by color Doppler imaging: A possible additional aid for the follow up of patients with gestational trophoblastic tumors 78
Unilocular adnexal cysts with papillary projections but no other solid components: is there a diagnostic method that can reliably classify them as benign or malignant before surgery? 77
Tumor volume as risk factor for nodal diffusion in endometrial cancer 77
Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas 75
Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel 75
Brain metastases from endometrial carcinoma 72
Fertility-sparing surgery in uterine leiomyosarcoma 67
Could different follow-up modalities play a role in the diagnosis of asymptomatic endometrial cancer relapses?: an Italian multicentric retrospective analysis 67
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial 67
Paclitaxel, ifosfamide and cisplatin (TIP) chemotherapy for recurrent or persistent squamous-cell cervical cancer 66
Comparison of methods for monitoring young women with stage I borderline ovarian tumor after conservative surgery 65
Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel 65
Neoplasie dell’apparato genitale femminile 64
ΔNp63 expression is associated with poor survival in ovarian cancer 62
Neoadjuvant chemotherapy with cisplatin, ifosfamide and paclitaxel for locally advanced squamous-cell cervical cancer 62
Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer 61
Surgical resection of solitary brain metastasis from ovarian carcinoma: an analysis of 22 cases 60
Total neuropathy scale items as early predictors of chemotherapy‐induced peripheral neurotoxicity 59
Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial 59
A prospective study of the role of ultrasound in the management of adnexal masses in pregnancy 58
Diagnostic accuracy of transvaginal ultrasound examination for assigning a specific diagnosis to adnexal masses 56
Conservative treatment followed by chemotherapy with doxorubicin and ifosfamide for cervical sarcoma botryoides in young females 55
Ultrasound-guided aspiration of endometriomas: Possible applications and limitations 54
Totale 11.523
Categoria #
all - tutte 26.873
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.873

Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.024 0 0 14 7 21 128 65 58 58 129 296 248
2019/20202.771 341 165 218 246 268 335 369 191 286 119 187 46
2020/20211.878 124 82 178 186 122 153 192 179 195 208 104 155
2021/20221.170 74 89 81 112 105 94 51 90 56 85 103 230
2022/20231.965 252 573 133 137 181 295 30 98 134 30 66 36
2023/2024169 44 54 71 0 0 0 0 0 0 0 0 0
Totale 11.818